Similar articles

• Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

  Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Nakahara H, et al. Arthritis Rheum. 2003 Jun;48(6):1521-9. doi: 10.1002/art.11143. Arthritis Rheum. 2003. PMID: 12794819
• Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

  Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Paleolog EM, et al. Arthritis Rheum. 1998 Jul;41(7):1258-65. doi: 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1. Arthritis Rheum. 1998. PMID: 9663484 Clinical Trial.
• Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta.

  Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD. Jackson JR, et al. J Rheumatol. 1997 Jul;24(7):1253-9. J Rheumatol. 1997. PMID: 9228120
• [Hair follicles and vascular endothelial growth factor].

  Lachgar S, Charvéron M, Aries MF, Gall Y, Bonafé JL. Lachgar S, et al. Ann Dermatol Venereol. 1998 Apr;125(4):271-4. Ann Dermatol Venereol. 1998. PMID: 9747267 Review. French. No abstract available.
• [MRA for therapy of rheumatoid arthritis].

  Nishimoto N, Mihara M. Nishimoto N, et al. Nihon Rinsho. 2005 Jan;63 Suppl 1:538-43. Nihon Rinsho. 2005. PMID: 15799414 Review. Japanese. No abstract available.